An FDA Perspective on the Regulatory Implications of Complex Signatures to Predict Response to Targeted Therapies

Clinical Cancer Research - United States
doi 10.1158/1078-0432.ccr-16-1098
Full Text
Abstract

Available in full text

Date
Authors
Publisher

American Association for Cancer Research (AACR)

Related search

A View on EGFR-targeted Therapies From the Oncogene-Addiction Perspective

Frontiers in Pharmacology
Pharmacology
2013English

Response to FDA Commissioner's Statement on Dsuvia Approval

Addiction
MedicinePsychiatryMental Health
2019English

From Biochemical Analysis to Targeted Therapies

Fibrogenesis and Tissue Repair
DermatologyMedicineHepatologyRheumatologyGastroenterology
2012English

Targeted Therapies to Improve Tumor Immunotherapy

Clinical Cancer Research
Cancer ResearchOncology
2008English

Finding a Cure for Tuberous Sclerosis Complex: From Genetics Through to Targeted Drug Therapies

Advances in Genetics
MedicineGenetics
2019English

Genetic Markers Predict Primary Non-Response and Durable Response to Anti-TNF Biologic Therapies in Crohn’s Disease

American Journal of Gastroenterology
HepatologyGastroenterology
2016English

Thymic Malignancies: From Clinical Management to Targeted Therapies

Journal of Clinical Oncology
Cancer ResearchMedicineOncology
2011English

Response to Intervention (RTI) Services: An Ecobehavioral Perspective

Journal of Educational and Psychological Consultation
DevelopmentalPsychologyEducational Psychology
2012English

Pupillary Response to Complex Interdependent Tasks: A Cognitive-Load Theory Perspective

Behavior Research Methods
DevelopmentalArtsPsychologyEducational PsychologyCognitive PsychologyHumanitiesExperimental
2016English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy